Evidence map›Paper›PMID 35239855›Full record

Trial reportRevista do Colegio Brasileiro de Cirurgioes2022

A phase 2 trial of short-course Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) at interval cytoreductive surgery (iCRS) for advanced ovarian cancer.

Thales Paulo Batista, Vandré Cabral Gomes Carneiro, Rodrigo Tancredi, Levon Badiglian Filho, Ronaldo Lúcio Costa Rangel, André Lopes, Bruno José Queiroz Sarmento, Cristiano Souza Leão

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Revista do Colegio Brasileiro de Cirurgioes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Thales Paulo Batista- IMIP - Instituto de Medicina Integral Professor Fernando Figueira, Department of Surgery/Oncology - Recife - PE - Brasil.ORCID http://orcid.org/0000-0001-5320-3205
Vandré Cabral Gomes Carneiro- IMIP - Instituto de Medicina Integral Professor Fernando Figueira, Department of Surgery/Oncology - Recife - PE - Brasil.ORCID http://orcid.org/0000-0001-8776-8837
Rodrigo Tancredi- IMIP - Instituto de Medicina Integral Professor Fernando Figueira, Department of Clinical Oncology - Recife - PE - Brasil.
Levon Badiglian Filho- AC Camargo Cancer Center, Department of Gynecology - São Paulo - SP - Brasil.ORCID http://orcid.org/0000-0001-8741-166X
Ronaldo Lúcio Costa Rangel- IBCC - Instituto Brasileiro de Controle do Câncer, Department of Gynecology - São Paulo - SP - Brasil.ORCID http://orcid.org/0000-0002-4794-993X
André Lopes- IBCC - Instituto Brasileiro de Controle do Câncer, Department of Gynecology - São Paulo - SP - Brasil.ORCID http://orcid.org/0000-0002-4986-8738
Bruno José Queiroz Sarmento- IHBDF - Instituto Hospital de Base do Distrito Federal, Serviço de Oncologia Cirúrgica - Brasília - DF - Brasil.ORCID http://orcid.org/0000-0001-9023-8554
Cristiano Souza Leão- IMIP - Instituto de Medicina Integral Professor Fernando Figueira, Departamento de Cirurgia - Recife - PE - Brasil.ORCID http://orcid.org/0000-0003-2989-117X
Hospital de Câncer de Pernambuco · BRInstituto Brasileiro de Controle do Câncer · BRAC Camargo Hospital · BRHospital de Base · BRInstituto de Medicina Integral Professor Fernando Figueira · BRUniversidade Federal de Pernambuco · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveto report the final analysis of a phase 2 trial assessing the efficacy and safety of short-course hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with advanced epithelial ovarian cancer (EOC).

methodsthis was an open-label, multicenter, single-arm trial of HIPEC in patients with advanced EOC who underwent interval cytoreductive surgery (iCRS) after neoadjuvant chemotherapy (NACT). HIPEC was performed as a concentration-based regimen of platinum-based chemotherapy for 30 minutes. Primary endpoint was the rate of disease progression occurring at nine months following iCRS plus HIPEC (PD9). Secondary endpoints were postoperative complications, time to start adjuvant chemotherapy, length of hospital and ICU stay, quality of life (QoL) over treatment, and ultimately 2-year progression-free survival (PFS) and overall survival (OS). Analysis was by intention-to-treat with final database lock for survival outcomes on February 23, 2021.

resultsfifteen patients with stage III EOC were enrolled between February 2015 and July 2019, in four centers. The intention to treat PD9 was 6.7%. With a median follow-up of 33 months (IQR, 24.3-46.5), the median PFS was 18.1 months and corresponding 2-year rates of PFS and OS was 33.3% and 93.3%, respectively. Three patients (20%) experienced graded III complications. Median length of hospital and ICU stay was 5 (IQR, 4-6.5) and 1 (IQR, 1-1) days, respectively. Time to restart systemic chemotherapy was 39 (IQR, 35-49.3) days and no significant difference over time in QoL was observed.

conclusionswe demonstrate preliminary efficacy and safety of short-course HIPEC in patient with advanced EOC.

Indexed as

Cytoreduction Surgical ProceduresOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Ovarian EpithelialHumansHyperthermic Intraperitoneal ChemotherapyQuality of Life

Identifiers

PMID35239855
PMCPMC10578806
OpenAlexW4214933161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.